SINTX Receives Issuance of U.S. Patent for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic Biomaterial
February 19 2025 - 5:00AM
SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”)
an advanced ceramics company specializing in the development and
commercialization of materials, components, and technologies for
medical and technical applications, today announced the issuance of
U.S. Patent No. 12,239,761 by the United States Patent and
Trademark Office (USPTO).
This newly issued patent strengthens SINTX’s
intellectual property portfolio, further solidifying its position
as a global leader in silicon nitride innovation. The patent covers
novel advancements in silicon nitride material processing and
applications, particularly in the biomedical sector, where the
company continues to make significant strides in next-generation
implant technology.
“This patent represents another key milestone in
SINTX’s ongoing commitment to pioneering advanced silicon nitride
solutions,” said Eric K. Olson, President and CEO of SINTX. “With
its antiviral, antibacterial, and biomechanical advantages, silicon
nitride continues to demonstrate its potential in medical implants,
regenerative medicine, and advanced coating technologies. This
latest patent reinforces our leadership in the field and
strengthens our ability to develop high-performance biomedical
applications.”
The patent, developed by the Company covers
innovative methods of adhering silicon nitride to a wide array of
biomaterial substrates to improve biocompatibility and resistance
to infection, expanding its potential applications to orthopedic,
craniomaxillofacial, dental and spinal implants. This scientific
breakthrough aligns with SINTX’s broader mission to leverage its
proprietary technology to improve patient outcomes and surgical
success rates.
SINTX is the only FDA-registered producer of
implantable silicon nitride, with a robust portfolio that includes
monolithic ceramic implants, particulate-based coatings,
microspheres and composite materials. These innovations are aimed
at enhancing osseointegration and reducing bacterial colonization,
key factors in improving implant longevity and patient safety.
With this issuance, SINTX continues to expand
its intellectual property portfolio, which now includes 17 issued
U.S. patents and 84 pending applications worldwide.
For more information about SINTX Technologies
and its silicon nitride platform, visit www.sintx.com.
About SINTX Technologies, Inc.
SINTX Technologies is an advanced ceramics
company that develops and commercializes materials, components, and
technologies for medical and technical applications. SINTX is a
global leader in the research, development, and manufacturing of
silicon nitride, and its products have been implanted in humans
since 2008. Over the past several years, SINTX has utilized
strategic acquisitions and alliances to enter into new markets. The
Company has manufacturing and R&D facilities in Utah and
Maryland.
For more information on SINTX Technologies or its materials
platform, visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (“PSLRA”) that are subject to a number of risks
and uncertainties. Forward-looking statements can be identified by
words such as: "anticipate," "believe," "project," "estimate,"
"expect," "strategy,” "future," "likely," "may," "should," "will"
and similar references to future periods. Examples of
forward-looking statements include, among others, statements we
make that the company continues to make significant strides in
next-generation implant technology and the potential to pursue
growth opportunities and explore strategic opportunities.
Readers are cautioned not to place undue
reliance on the forward-looking statements, which speak only as of
the date on which they are made and reflect management’s current
estimates, projections, expectations and beliefs. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of our
control. Our actual results and financial condition may differ
materially from those indicated in the forward-looking statements.
Important factors that could cause our actual results and financial
condition to differ materially from those indicated in the
forward-looking statements include, among others, technical
feasibility and product development. A discussion of other risks
and uncertainties that could cause our actual results and financial
condition to differ materially from those indicated in the
forward-looking statements can be found in SINTX’s Risk Factors
disclosure in its Annual Report on Form 10-K, filed with the SEC on
March 27, 2024, and in SINTX’s other filings with the SEC. SINTX
undertakes no obligation to publicly revise or update the
forward-looking statements to reflect events or circumstances that
arise after the date of this report, except as required by law.
Business and Media Inquiries for SINTX:SINTX
Technologies801.839.3502IR@sintx.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Jan 2025 to Feb 2025
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Feb 2024 to Feb 2025